Related Experiment Video

Updated: Jun 9, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Effect of glucagon-like peptide-1 receptor agonists on prostate cancer: A review

Xu Yu1, Jie Liu2

  • 1Linyi People's Hospital of Shandong Second Medical University, Weifang, Shandong, China.

Medicine
|October 28, 2024
PubMed

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used for type 2 diabetes, show potential in prostate cancer treatment. Further research explores GLP-1 receptor expression and GLP-1RA effects on prostate cancer.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for type 2 diabetes mellitus (T2DM).
  • GLP-1RAs exhibit significant hypoglycemic effects, promote weight loss, and have a favorable side effect profile.
  • Emerging evidence suggests GLP-1RAs may influence tumor development, including prostate cancer.

Purpose of the Study:

  • To investigate the expression of the glucagon-like peptide-1 receptor (GLP-1R) in prostate cancer.
  • To evaluate the effects of GLP-1RAs on prostate cancer.
  • To explore novel therapeutic strategies for prostate cancer utilizing GLP-1RAs.

Main Methods:

  • Review of existing literature on GLP-1R expression in prostate cancer.
  • Analysis of studies investigating the impact of GLP-1RAs on prostate cancer cell lines and animal models.
  • Examination of clinical data regarding GLP-1RA use and cancer risk.

Main Results:

  • GLP-1R is expressed in various human cells and tissues, including prostate cancer.
  • GLP-1RAs have demonstrated both inhibitory and potentially adverse effects on tumor growth in preliminary studies.
  • The role of GLP-1RAs in prostate cancer requires further elucidation due to complex interactions.

Conclusions:

  • GLP-1R expression in prostate cancer warrants further investigation for targeted therapies.
  • GLP-1RAs present a potential new avenue for prostate cancer treatment, but careful consideration of oncological outcomes is necessary.
  • Understanding the dual role of GLP-1RAs in cancer is crucial for clinical application.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
549
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
161